News | May 30, 2025
Alkem reports 7.1% YoY revenue growth in Q4 FY25
Annual EBITDA margin expands by 170 basis points
Annual EBITDA margin expands by 170 basis points
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
The initiative was announced at World Hypertension Congress, Chennai
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Subscribe To Our Newsletter & Stay Updated
